Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.

ABSTRACT:

Background

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven to be a successful strategy for prevent severe infections. CoronaVac and BNT162b2 are the most used vaccines worldwide, but their use in heterologous vaccination schedules is still subjected to evaluation.

Methods

Fifty healthy individuals who received heterologous prime-boost vaccination with CoronaVac and BNT162b2 were enrolled in a post-vaccination serological follow-up longitudinal prospective study. We evaluated specific serum anti-receptor binding domain (RBD) IgG antibody levels, and their capacity to block RBD-ACE2 interaction with a surrogate neutralization assay. In 20 participants, we assessed antibody binding kinetics by surface plasmon resonance, and Fc-mediate

SUBMITTER: Rammauro F 

PROVIDER: S-EPMC9352561 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature